SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.22+0.7%10:33 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (10411)2/12/2004 12:13:32 PM
From: Biomaven  Read Replies (3) of 52153
 
I didn't say less rigor applied to safety - just that efficacy be left for a later date. Likely insurance wouldn't pay for drugs where efficacy isn't approved anyhow, so there would still be an incentive to get efficacy approval.

Accutane is used for disfiguring acne - not what I would describe as a few pimples. Main safety concern is pregnancy, but that isn't an issue for males.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News